End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3222 USD | -2.36% | +2.32% | -20.05% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 9.98 | 129.4 | 177.5 | 22.43 | 23.62 | 17.39 | - | - |
Enterprise Value (EV) 1 | 9.98 | 129.4 | 177.5 | 22.43 | 23.62 | 17.39 | 17.39 | 17.39 |
P/E ratio | -0.06 x | -1.23 x | -1.38 x | -0.12 x | -0.06 x | -0.18 x | -0.26 x | -0.36 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 3.04 x | 1.06 x | 0.96 x | 0.55 x |
EV / Revenue | - | - | - | - | 3.04 x | 1.06 x | 0.96 x | 0.55 x |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 42.7 | 958 | 2,481 | 9,206 | 58,615 | 95,544 | - | - |
Reference price 2 | 234.0 | 135.0 | 71.54 | 2.436 | 0.4030 | 0.1820 | 0.1820 | 0.1820 |
Announcement Date | 24/03/20 | 15/03/21 | 14/03/22 | 13/03/23 | 01/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 7.768 | 16.33 | 18.2 | 31.84 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -28.83 | -50.51 | -92.31 | -112.1 | -118.4 | -97.14 | -89.45 | -85.9 |
Operating Margin | - | - | - | - | -1,523.94% | -594.77% | -491.48% | -269.8% |
Earnings before Tax (EBT) 1 | -28.62 | -50.46 | -92.29 | -110.2 | -116.7 | -117.1 | -123.1 | -124.5 |
Net income 1 | -31.09 | -52.17 | -92.29 | -116.9 | -116.7 | -96.14 | -88.6 | -85.05 |
Net margin | - | - | - | - | -1,501.78% | -588.64% | -486.81% | -267.13% |
EPS 2 | -3,866 | -110.0 | -52.00 | -20.44 | -6.850 | -1.007 | -0.6900 | -0.5100 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 24/03/20 | 15/03/21 | 14/03/22 | 13/03/23 | 01/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | 3.989 | 3.779 | 3.867 | 3.9 | 4.267 | 4.3 | 4.2 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -18.54 | -29.56 | -26.44 | -23.34 | -29.59 | -32.73 | -33.9 | -29 | -28.15 | -27.33 | -28.6 | -29 | -29.5 | -30.5 | - |
Operating Margin | - | - | - | - | - | - | - | - | -705.62% | -723.18% | -739.65% | -743.59% | -691.41% | -709.3% | - |
Earnings before Tax (EBT) 1 | -18.53 | -29.55 | -26.42 | -23.14 | -28.98 | -31.68 | -33 | -28.36 | -27.98 | -27.32 | -28.5 | -28.9 | -29.4 | -30.4 | - |
Net income 1 | -18.53 | -29.55 | -26.42 | -27.4 | -28.98 | -34.08 | -33 | -28.36 | -27.98 | -27.32 | -28.5 | -28.9 | -29.4 | -30.4 | - |
Net margin | - | - | - | - | - | - | - | - | -701.3% | -723% | -737.07% | -741.03% | -689.06% | -706.98% | - |
EPS 2 | -10.00 | -14.00 | -10.00 | -7.625 | -4.312 | -3.500 | -3.250 | -2.680 | -1.830 | -1.820 | -0.3400 | -0.2467 | -0.2267 | -0.2200 | -0.2000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 08/11/21 | 14/03/22 | 09/05/22 | 08/08/22 | 07/11/22 | 13/03/23 | 08/05/23 | 10/08/23 | 09/11/23 | 01/04/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 24/03/20 | 15/03/21 | 14/03/22 | 13/03/23 | 01/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-13.75% | 32.43B | |
+55.51% | 24.28B | |
-15.27% | 15.52B | |
-41.29% | 12.17B | |
-14.72% | 12.01B | |
-11.75% | 12B | |
+7.42% | 8.87B |
- Stock Market
- Equities
- TNXP Stock
- TNXP Stock
- Financials Tonix Pharmaceuticals